FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225556471> ?p ?o ?g. }

• W4225556471 endingPage "51" @default.
• W4225556471 startingPage "40" @default.
• W4225556471 abstract "PURPOSE Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor ixazomib combined with rituximab, in patients with relapsed WM. METHODS We conducted a multicenter phase I/II trial with ixazomib, rituximab, and dexamethasone (IRD). Induction consisted of eight cycles IRD wherein rituximab was started in cycle 3, followed by rituximab maintenance. Phase I showed feasibility of 4 mg ixazomib. Primary end point for phase II was overall response rate (ORR [≥ minimal response]) after induction. RESULTS A total of 59 patients were enrolled (median age, 69 years; range, 46-91 years). Median number of prior treatments was 2 (range, 1-7); 70% had an intermediate or high WM-IPSS (International Prognostic Scoring System for WM) score. After eight cycles, ORR was 71% (42 out of 59) (14% very good partial response [PR], 37% PR, and 20% minor response). Depth of response improved until month 12 (best ORR 85% [50 out of 59]: 15% very good PR, 46% PR, and 24% minor response). Median duration of response was 36 months. The average hematocrit level increased significantly (0.33-0.38 L/L) after induction ( P < .001). After two cycles of ixazomib and dexamethasone, immunoglobulin M levels decreased significantly (median 3,700-2,700 mg/dL, P < .0001). Median time to first response was 4 months. Median progression-free survival and overall survival were not reached. After median follow-up of 24 months (range, 7.4-54.3 months), progression-free survival and overall survival were 56% and 88%, respectively. Toxicity included mostly grade 2 or 3 cytopenias, grade 1 or 2 neurotoxicity, and grade 2 or 3 infections. No infusion-related reactions or immunoglobulin M flare occurred with use of subcutaneous rituximab. Quality of life improved significantly after induction. In total, 48 patients (81%) completed at least six cycles of IRD. CONCLUSION Combination of IRD shows promising efficacy with manageable toxicity in patients with relapsed or refractory WM." @default.
• W4225556471 created "2022-05-05" @default.
• W4225556471 creator A5007493880 @default.
• W4225556471 creator A5010979808 @default.
• W4225556471 creator A5016577574 @default.
• W4225556471 creator A5025773174 @default.
• W4225556471 creator A5036293139 @default.
• W4225556471 creator A5044599883 @default.
• W4225556471 creator A5047666215 @default.
• W4225556471 creator A5049413660 @default.
• W4225556471 creator A5049740797 @default.
• W4225556471 creator A5054397552 @default.
• W4225556471 creator A5067093272 @default.
• W4225556471 creator A5068092554 @default.
• W4225556471 creator A5071082159 @default.
• W4225556471 creator A5073215615 @default.
• W4225556471 creator A5086774598 @default.
• W4225556471 creator A5088691462 @default.
• W4225556471 creator A5091600816 @default.
• W4225556471 date "2022-01-01" @default.
• W4225556471 modified "2023-09-25" @default.
• W4225556471 title "Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study" @default.
• W4225556471 cites W1786721594 @default.
• W4225556471 cites W1949051914 @default.
• W4225556471 cites W1979068418 @default.
• W4225556471 cites W2010329820 @default.
• W4225556471 cites W2026010194 @default.
• W4225556471 cites W2037983836 @default.
• W4225556471 cites W2069021241 @default.
• W4225556471 cites W2071957083 @default.
• W4225556471 cites W2074051660 @default.
• W4225556471 cites W2091319225 @default.
• W4225556471 cites W2095384810 @default.
• W4225556471 cites W2116979483 @default.
• W4225556471 cites W2121288264 @default.
• W4225556471 cites W2128490833 @default.
• W4225556471 cites W2133192145 @default.
• W4225556471 cites W2133201432 @default.
• W4225556471 cites W2148009655 @default.
• W4225556471 cites W2150724746 @default.
• W4225556471 cites W2160940401 @default.
• W4225556471 cites W2194688567 @default.
• W4225556471 cites W2310716991 @default.
• W4225556471 cites W2485213074 @default.
• W4225556471 cites W2556821739 @default.
• W4225556471 cites W2673256467 @default.
• W4225556471 cites W2799835249 @default.
• W4225556471 cites W2884164278 @default.
• W4225556471 cites W2898129912 @default.
• W4225556471 cites W2963730114 @default.
• W4225556471 cites W2971082993 @default.
• W4225556471 cites W3000412533 @default.
• W4225556471 cites W3080202060 @default.
• W4225556471 cites W3085746633 @default.
• W4225556471 cites W3108826455 @default.
• W4225556471 doi "https://doi.org/10.1200/jco.21.00105" @default.
• W4225556471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34388022" @default.
• W4225556471 hasPublicationYear "2022" @default.
• W4225556471 type Work @default.
• W4225556471 citedByCount "20" @default.
• W4225556471 countsByYear W42255564712022 @default.
• W4225556471 countsByYear W42255564712023 @default.
• W4225556471 crossrefType "journal-article" @default.
• W4225556471 hasAuthorship W4225556471A5007493880 @default.
• W4225556471 hasAuthorship W4225556471A5010979808 @default.
• W4225556471 hasAuthorship W4225556471A5016577574 @default.
• W4225556471 hasAuthorship W4225556471A5025773174 @default.
• W4225556471 hasAuthorship W4225556471A5036293139 @default.
• W4225556471 hasAuthorship W4225556471A5044599883 @default.
• W4225556471 hasAuthorship W4225556471A5047666215 @default.
• W4225556471 hasAuthorship W4225556471A5049413660 @default.
• W4225556471 hasAuthorship W4225556471A5049740797 @default.
• W4225556471 hasAuthorship W4225556471A5054397552 @default.
• W4225556471 hasAuthorship W4225556471A5067093272 @default.
• W4225556471 hasAuthorship W4225556471A5068092554 @default.
• W4225556471 hasAuthorship W4225556471A5071082159 @default.
• W4225556471 hasAuthorship W4225556471A5073215615 @default.
• W4225556471 hasAuthorship W4225556471A5086774598 @default.
• W4225556471 hasAuthorship W4225556471A5088691462 @default.
• W4225556471 hasAuthorship W4225556471A5091600816 @default.
• W4225556471 hasBestOaLocation W42255564711 @default.
• W4225556471 hasConcept C126322002 @default.
• W4225556471 hasConcept C141071460 @default.
• W4225556471 hasConcept C141341695 @default.
• W4225556471 hasConcept C2776063141 @default.
• W4225556471 hasConcept C2776364478 @default.
• W4225556471 hasConcept C2776391228 @default.
• W4225556471 hasConcept C2777063308 @default.
• W4225556471 hasConcept C2779338263 @default.
• W4225556471 hasConcept C2780108899 @default.
• W4225556471 hasConcept C2780401358 @default.
• W4225556471 hasConcept C2780653079 @default.
• W4225556471 hasConcept C2781038049 @default.
• W4225556471 hasConcept C2781098529 @default.
• W4225556471 hasConcept C29730261 @default.
• W4225556471 hasConcept C71924100 @default.
• W4225556471 hasConcept C90924648 @default.
• W4225556471 hasConceptScore W4225556471C126322002 @default.

• next